RecruitingEarly Phase 1NCT05804227

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Sponsor

M.D. Anderson Cancer Center

Enrollment

40 participants

Start Date

Apr 20, 2023

Study Type

INTERVENTIONAL

Conditions

Gliomas

Summary

To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ulixertinib and a drug called Ulixertinib for people with gliomas. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUlixertinib

Surgical: Only adults with recurrent MAPK-activated gliomas will be accrued to the surgical cohort. Patients will receive Ulixertinib by mouth twice a day for two weeks and will undergo tumor resection subsequently on day 14 (+/- 3 working days).

DRUGUlixertinib

Non-Surgical: Patients (12 years and above) with MAPK-activated gliomas will receive Ulixertinib by mouth twice a day continuously on a daily basis for cycles of 28 day.